文献速递基础与转化研究新药、器械与细胞基因治疗研发

整合素β7活化构象是多发性骨髓瘤CAR T细胞治疗的新靶点

The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy.
PubMed 文献 · Nat Med · 2017-11-06

研究筛选超过10,000个抗多发性骨髓瘤(MM)单克隆抗体克隆,鉴定出MMG49能特异性识别整合素β7的活化构象。MMG49衍生的CAR T细胞在体外和体内发挥抗MM效应,且不损伤正常造血细胞,提示该构象可作为癌症免疫治疗靶点。

要点

  • MMG49识别整合素β7 N端区域的活化构象表位,静息构象中不可及。
  • MM细胞高表达并组成性活化整合素β7,赋予高MMG49反应性。
  • MMG49 CAR T细胞发挥抗MM效应,不损伤正常造血细胞。

核心结论

  • 整合素β7的活化构象可作为多发性骨髓瘤特异性治疗靶点,MMG49 CAR T细胞疗法具有前景。

研究设计与样本

  • 筛选超过10,000个抗MM单克隆抗体克隆,鉴定MMG49;构建MMG49衍生CAR T细胞,评估抗MM效应及对正常造血细胞的影响。

主要发现

  • MMG49特异性识别整合素β7活化构象的N端区域表位,静息构象中不可及。
  • MM细胞因整合素β7高表达和组成性活化而呈高MMG49反应性,其他细胞类型包括正常整合素β7+淋巴细胞几乎检测不到MMG49结合。
  • MMG49 CAR T细胞发挥抗MM效应,不损伤正常造血细胞。

临床怎么用

  • MMG49 CAR T细胞疗法可能用于多发性骨髓瘤治疗,但需进一步临床验证。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer-specific cell-surface antigens are ideal targets for monoclonal antibody (mAb)-based immunotherapy but are likely to have previously been identified in transcriptome or proteome analyses. Here, we show that the active conformer of an integrin can serve as a specific therapeutic target for multiple myeloma (MM). We screened >10,000 anti-MM mAb clones and identified MMG49 as an MM-specific mAb specifically recognizing a subset of integrin β7 molecules. The MMG49 epitope, in the N-terminal region of the β7 chain, is predicted to be inaccessible in the resting integrin conformer but exposed in the active conformation. Elevated expression and constitutive activation of integrin β7 conferred high MMG49 reactivity on MM cells, whereas MMG49 binding was scarcely detectable in other cell types including normal integrin β7+ lymphocytes. T cells transduced with MMG49-derived chimeric antigen receptor (CAR) exerted anti-MM effects without damaging normal hematopoietic cells. Thus, MMG49 CAR T cell therapy is promising for MM, and a receptor protein with a rare but physiologically relevant conformation can serve as a cancer immunotherapy target.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Hosen N, Matsunaga Y, Hasegawa K, et al. The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy. Nat Med. 2017. PMID: 29106400. doi:10.1038/nm.4431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。